Jonathan Silverberg, MD, PhD, MPH

Silverberg discussers 16-week data for rezpegaldesleukin in atopic dermatitis from the phase 2b REZOLVE-AD trial.

Silverberg discusses the significance of the dupilumab approval in BP and why he thinks it's the most important news in dermatology in 2025 so far.

In this Q&A interview, Silverberg highlighted takeaways from his talk at RAD 2025 on recent FDA approvals for atopic dermatitis.

Looking to the future of atopic dermatitis treatment, the panel discusses ongoing research and promising emerging therapies.

Focusing on clinical scenarios, experts on atopic dermatitis discuss how their treatment approaches vary depending on patient-specific factors.

Dermatologists outline the role of targeted therapies and JAK inhibitors in the treatment of patients with atopic dermatitis.

Following a review of findings from the LEVEL UP study, an expert on atopic dermatitis shares what we’ve learned from long-term data on upadacitinib and JAKi.

Jonathan Silverberg, MD, PhD, MPH, reviews findings from the LEVEL UP study investigating upadacitinib in patients with moderate-to-severe atopic dermatitis.

Lindsay S. Ackerman, MD, FAAD, and Jonathan Silverberg, MD, PhD, MPH, provide clinical insights on best practices for monitoring patients with atopic dermatitis who are receiving JAK inhibitors.

Experts on atopic dermatitis compare the safety profile of JAK inhibitors with traditional and more advanced treatments currently available for patients.

A panel of dermatologists discuss the evolution of JAK inhibitors for atopic dermatitis and how they fit into current treatment paradigms.

Focusing on the complex pathophysiology of atopic dermatitis, Lindsay S. Ackerman, MD, FAAD, discusses the importance of looking beyond type 2 inflammation while treating patients.

Dermatologists outline unmet needs in the treatment landscape for atopic dermatitis and discuss how to potentially improve the standard of care for patients with atopic dermatitis.

The panel provides comprehensive insights on treating atopic dermatitis and how recent advances have elevated standard-of-care treatment practices in dermatology practices.

A panel of experts on atopic dermatitis discuss how patient preferences are taken into account when choosing between available treatments.

Jonathan Silverberg, MD, PhD, MPH, offers insights on the role of patient-reported outcomes in informing treatment decisions for patients with atopic dermatitis.

Lindsay S. Ackerman, MD, FAAD, provides clinical insights on best practices for evaluating treatment response in patients with atopic dermatitis.

Lindsay S. Ackerman, MD, FAAD, and Jonathan Silverberg, MD, PhD, MPH, discuss how patient goals inform treatment decisions for patients with atopic dermatitis.

Experts on atopic dermatitis describe the burden of the disease and provide clinical insights on counseling patients who are experiencing sleep disturbances.

A panel of dermatologists discuss the heterogeneity of clinical presentations of atopic dermatitis and offer ways to reduce misdiagnosis.